Tilray Inc. ($TLRY) Stock Forecast: Up 5.3% Today

What is Tilray Inc.?

Tilray (TLRY) is a cannabis company that has experienced challenges in profitability and revenue growth recently. Although diversification attempts have been made, the company's stock performance has been declining.

Why is Tilray Inc. going up?

TLRY stock is up 5.3% on Feb 24, 2026 16:16

• Despite a new exclusive licensing deal for beer distribution in the U.S. with Carlsberg, Tilray's stock continues to struggle, reflecting ongoing financial difficulties and consistent share price decline.
• The company's active acquisition strategy and continual cash consumption have led to a decrease in shareholder value, prompting analysts to recommend exploring other investment options.
• Despite a slight decrease in Tilray's stock value during a bullish market period, investors are eagerly awaiting the upcoming earnings report, hoping for positive growth in both earnings per share and revenue for the quarter.
• The exclusive U.S. licensing agreement with Carlsberg aims to enhance Tilray's presence in the beverage market but market sentiment remains cautious due to the company's historical performance and limited growth prospects.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Is It Time to Dump Your Shares of Tilray?

Tilray (NASDAQ: TLRY) has significantly underperformed, with its stock down 97% over five years, primarily due to excessive share dilution and slow growth in the cannabis market. Despite becoming one of the largest cannabis companies, Tilray has struggled with profitability and modest revenue growth. The article suggests that given its past performance and limited growth prospects, investors might be better off divesting from Tilray and seeking other opportunities.

https://www.theglobeandmail.com/investing/markets/stocks/TLRY-Q/pressreleases/363330/is-it-time-to-dump-your-shares-of-tilray/

Tilray Shares Struggle to Gain Traction Despite Strategic Beer Deal

Tilray's stock continues to face significant headwinds despite announcing an exclusive, multi-year licensing deal with Carlsberg for beer distribution in the U.S., starting in 2027. Investors are more focused on immediate financial challenges and the company's persistent share price weakness, which has seen a 97% decline over five years due to factors like share dilution and a recent reverse stock split. While the company reported record Q2 2026 revenue driven by cannabis sales, its beverage segment declined, and analyst sentiment remains cautious.

https://www.ad-hoc-news.de/boerse/news/ueberblick/tilray-shares-struggle-to-gain-traction-despite-strategic-beer-deal/68604933

Tilray Shareholder Value Continues to Dwindle

Tilray's share count has dramatically increased since its 2018 market debut, leading to substantial erosion of shareholder value, with its stock declining significantly over the past five years. Despite substantial annual sales, the company consistently burns cash and faces a bleak market outlook with limited growth projections. Analysts are recommending investors consider other stocks due to Tilray's ongoing profitability issues and aggressive acquisition strategy.

https://intellectia.ai/news/stock/tilray-shareholder-value-continues-to-dwindle

Tilray Brands, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know

Tilray Brands, Inc. (TLRY) saw its stock close down by 1.77% at $7.75, underperforming the broader market. The company's shares have dropped 13.58% over the past month. Investors are anticipating its upcoming earnings release, with predictions of 86% EPS growth and 10.85% revenue increase for the quarter, and currently holds a Zacks Rank of #3 (Hold).

https://www.bitget.com/amp/news/detail/12560605211402

Tilray Lands Exclusive U.S. License for Carlsberg Beers

Tilray Brands, Inc. secured an exclusive five-year licensing agreement with the Carlsberg Group to produce, market, sell, and distribute several Carlsberg-branded beers in the U.S. starting January 1, 2027. This partnership aims to strengthen Tilray's beverage platform, drive volume growth, and expand market share for premium European beers in the U.S.

https://nationaltoday.com/us/ny/new-york/news/2026/02/21/tilray-lands-exclusive-u-s-license-for-carlsberg-beers/

Trending Today

Verisk Analytics Inc. ($VRSK) Stock Forecast: Up 5.2% Today

Keysight Technologies Inc. ($KEYS) Stock Forecast: Up 22.2% Today

Bumble Inc. ($BMBL) Stock Forecast: Up 5.1% Today

PayPal Holdings Inc. ($PYPL) Stock Forecast: Up 6.8% Today

Ubiquiti ($UI) Stock Forecast: Up 5.1% Today

Expeditors International of Washington Inc. ($EXPD) Stock Forecast: Down 7.9% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 6.9% Today

Innovative Industrial Properties Inc ($IIPR) Stock Forecast: Up 10.6% Today

Expedia Group Inc. ($EXPE) Stock Forecast: Up 5.1% Today

Delta Air Lines Inc. ($DAL) Stock Forecast: Up 5.1% Today

Tilray Inc. Price History

29.00.2026 - TLRY Stock was down 7.2%

• Tilray's stock plummeted by 3.6% recently due to various reasons:
• Analyst downgrades and missing earnings per share (EPS) figures in the most recent report raised concerns among investors, leading to a decline in stock value.
• The stock's movement below its 50-day and 200-day moving averages signifies a pessimistic market sentiment.
• Despite positive updates about expanding its European medical cannabis platform in Italy, the company encounters obstacles like regulatory challenges, competition from multi-state operators, and high short interest, contributing to its overall underwhelming performance.
• Although the announcement of the SweetWater 420 Fest by Tilray's branch, SweetWater Brewing Company, was positive for the brand, it did not notably impact the stock's trajectory.
• Various analysts' price targets and ratings, for instance, Canaccord Genuity Group's hold rating and a price target of C$13.00, depict a cautious outlook on Tilray's stock performance in the near future.
• Investors keenly observe developments regarding the potential reclassification of U.S. medical cannabis and the company's efficacy in managing losses to evaluate future stock performance amidst previous declines and dilution risks.

13.00.2026 - TLRY Stock was down 5.3%

• Despite achieving record revenue and moving to a net cash position, Tilray's stock witnessed a notable bearish trend.
• The market reaction may have been influenced by a substantial EPS miss and deeply negative net margins, sparking investor concerns.
• Analysts recommending exploring alternative investment options despite increased positions from certain institutional investors might have exacerbated the bearish outlook.
• Ongoing worries surrounding operating losses, potential shareholder dilution, and the necessity for Tilray to capitalize on emerging market trends to enhance margins and cash flow likely played a role in the stock's bearish performance.

24.01.2026 - TLRY Stock was up 5.3%

• Despite a new exclusive licensing deal for beer distribution in the U.S. with Carlsberg, Tilray's stock continues to struggle, reflecting ongoing financial difficulties and consistent share price decline.
• The company's active acquisition strategy and continual cash consumption have led to a decrease in shareholder value, prompting analysts to recommend exploring other investment options.
• Despite a slight decrease in Tilray's stock value during a bullish market period, investors are eagerly awaiting the upcoming earnings report, hoping for positive growth in both earnings per share and revenue for the quarter.
• The exclusive U.S. licensing agreement with Carlsberg aims to enhance Tilray's presence in the beverage market but market sentiment remains cautious due to the company's historical performance and limited growth prospects.

22.00.2026 - TLRY Stock was up 5.1%

• TLRY stock experienced a strong bullish movement recently, possibly due to the launch of SweetWater's new high-ABV brew, Big Trip Double IPA, expanding its product offerings to cater to the craft beer market.
• The establishment of Tilray Medical Italia to strengthen its presence in Italy's medical cannabis market might have also played a role in the positive sentiment, demonstrating the company's dedication to increasing its international ventures.
• Despite facing recent share price challenges and analyst downgrades, the company's undervaluation as pointed out by Simply Wall St's analysis could have attracted value investors, contributing to the bullish movement.
• The bullish momentum in TLRY's stock today is thought to be driven by a combination of product expansion in the craft beer sector, strategic endeavors in the medical cannabis market, and potential value opportunities arising from recent price declines.

19.01.2026 - TLRY Stock was up 5.8%

• Tilray's stock experienced a strong bullish movement of over 4% following the announcement of the exclusive brewing and licensing agreement with Carlsberg Group.
• The partnership with Carlsberg is expected to bring immediate scale and revenue to Tilray, driving optimism among investors and leading to the bullish market movement.
• This strategic move aligns with Tilray's focus on partnering with established brands and maximizing its beverage operations, showcasing a promising future for the company in the competitive beer market.
• The market's positive reaction reflects investor confidence in Tilray's ability to leverage its operational infrastructure effectively and strengthen its position in the premium European segment of the US beer market.

05.01.2026 - TLRY Stock was down 6.6%

• The acknowledgment of Tilray Pharma's CC Pharma as a TOP 100 Innovator in Germany underlines the company's dedication to innovation and operational excellence within the pharmaceutical distribution industry.
• Notwithstanding this positive development, the decrease in Tilray Brands shares could be linked to profit-taking by investors following a recent uptrend or broader market uncertainties impacting the stock price.
• The forthcoming nationwide promotional campaign in Tilray's U.S. craft beer taprooms might have shifted investor attention away from the pharmaceutical sector, resulting in a temporary decline in the stock price.
• Investors may be anticipating the upcoming financial update in early April to evaluate the company's overall performance and growth trajectory, possibly influencing the bearish sentiment surrounding the stock today.

12.00.2026 - TLRY Stock was up 4.9%

• Reported a record Q2 Fiscal 2026 net revenue of $218 million, led by strong performance in international cannabis and Canadian adult-use cannabis segments.
• Transitioned to a net cash position and reaffirmed full-year Adjusted EBITDA guidance, highlighting disciplined execution and a strengthened balance sheet.
• Analysts' opinion that the recent share plunge was overdone aligns with financial results, suggesting potential undervaluation due to underestimation of profit growth in Canadian and international cannabis markets.
• Strategic expansion into the beverage segment, along with readiness to leverage medical cannabis infrastructure in the U.S., positions the company for future growth amidst potential regulatory shifts in the cannabis market.

28.00.2026 - TLRY Stock was down 5.2%

• Analyst downgrades and a significant earnings per share (EPS) miss contributed to a 3.6% drop in Tilray Brands' shares, leading to the stock trading below its key moving averages.
• Despite some institutional investment interest, the company reported a deeply negative net margin and is projected to have a negative EPS for the current year, impacting investor sentiment.
• The expansion of Tilray's European medical cannabis platform through Italy was seen as a positive move, but investors are still awaiting progress on U.S. medical cannabis reclassification and effective management of losses to mitigate risks.
• The launch of a new high-ABV beer by SweetWater Brewing Company, a subsidiary of Tilray Brands, did not seem to have a significant impact on the stock's bearish movement today.

16.00.2026 - TLRY Stock was down 5.1%

• Tilray's shares declined by 1.9% today, staying close to its 50-day moving average and below its 200-day average, indicating a bearish sentiment in the market.
• The company failed to meet quarterly EPS estimates and revealed negative net margins, resulting in a downgrade to a "strong sell" rating by Zacks Research.
• Despite achieving record Q2 revenues from international operations, Tilray's stock currently holds a Zacks Rank #5 (Strong Sell) primarily due to concerns about its US market prospects.
• Analysts have a cautious stance on Tilray's stock, advising investors to consider other investment opportunities in light of the company's financial performance and market outlook.

15.00.2026 - TLRY Stock was up 5.3%

• Tilray reported record Q2 revenues of $218 million, driven by international operations and distribution, showcasing the company's ability to capture market opportunities.
• Despite a recent EPS miss and negative net margins, the stock saw an increase as investors may be optimistic about the company's long-term growth prospects.
• The focus on higher-margin international markets and new THC beverage offerings indicates Tilray's commitment to diversification and sustainable profitability, which could have positively influenced investor sentiment.
• Analysts suggesting to consider other stocks for better investment opportunities may have created some uncertainty, but the overall market movement reflects confidence in Tilray's strategic direction and potential for future growth.

18.01.2026 - TLRY Stock was up 5.5%

• An analyst has given TLRY a Hold rating and set a price target of C$13, expressing concerns about the beer market and optimism regarding potential US legislation impact.
• Despite falling short of Q4 earnings projections and recording a negative net margin, Zacks Research upgraded its rating on TLRY from "strong sell" to "hold."
• A recent partnership with Smartway Pharmaceuticals to enhance the distribution of medical cannabis products in the UK has been seen as a strategic move that likely boosted investor confidence and contributed to positive stock movement.
• Institutional investors making changes to their holdings by either increasing or starting new positions in TLRY may have helped drive the stock price upwards.

10.01.2026 - TLRY Stock was up 5.2%

• Tilray's stock showed a robust 1.6% bullish movement today, disregarding recent downgrades and cautious analyst views.
• Q2 FY2026 saw the company achieving record net revenue due to growth in international medical cannabis sales and Canadian adult-use cannabis. This demonstrates its ability to navigate market fluctuations.
• The company's expansion of its U.S. beverage alcohol division and recognition of its German medical distribution subsidiary showcase strategic efforts to diversify revenue sources and bolster presence in key markets.
• Notwithstanding challenges like missed earnings estimates and negative net margin, Tilray's dual focus on medical cannabis and spirits sectors, along with international expansion, appears to have positively impacted investor sentiment and influenced today's bullish movement.